However, intrathecal injections of the TRPA1 antagonist CHEM-5861528 have been found to reverse mechanical allodynia in streptozotocin-induced diabetic rats (Wei et al. 2009; Wei et al. 2010) and may prevent diabetes-induced loss of nociceptor nerve endings in the skin (Koivisto et al. 2012). Here, TRPA1 is linked to diabetes mellitus.